News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 21, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 18, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
– First and Only Once-Daily , Fixed-Dose Combination of a Prostaglandin Analog and a Rho Kinase (ROCK) Inhibitor – – Rocklatan™ Demonstrated Statistical Superiority over Widely-Prescribed First-Line Agent Latanoprost – DURHAM, N.C. --(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% label
Toggle Summary Aerie Pharmaceuticals to Present at Two Investor Conferences in March
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 5, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update
Conference Call and Webcast Today, February 25 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Feb. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 19, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)
Phase 2 Clinical Study Initiating Later in First Quarter 2019 DURHAM, N.C. --(BUSINESS WIRE)--Jan. 17, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
Announces Opening of Tokyo Branch Office and Two Key Hires in Japan DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
TOP